Product How it works Pricing Blog FAQ About Contact
Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International (NASDAQ: KNSA) revenue

Kiniksa Pharmaceuticals International reported revenue of $677.6m for fiscal 2025, 60.1% more than in fiscal 2024 ($423.2m). Since fiscal 2021 its revenue has grown by 1,657.9%, an average growth of 104.8% a year.

Kiniksa Pharmaceuticals International has grown its revenue for 4 years in a row, and fiscal 2025 is the highest of its 5 fiscal years on record.

Revenue, in millions of US dollars38.52021220.22022270.32023423.22024677.62025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$677.6m+60.1%$77.2m11.4%
2024$423.2m+56.6%−$45.6m−10.8%
2023$270.3m+22.7%−$25.2m−9.3%
2022$220.2m+471.2%$9.8m4.4%
2021$38.5m—−$156.6m−406.4%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Kiniksa Pharmaceuticals International revenue compared with its sector

By revenue for its latest fiscal year, Kiniksa Pharmaceuticals International ranks 177th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Kiniksa Pharmaceuticals International, 60.1%.

RankCompanyRevenueRevenue growth
175thPacira Biosciences$726.4m3.6%
176thAmphastar Pharmaceuticals$719.9m−1.7%
177thKiniksa Pharmaceuticals International$677.6m60.1%
178thUltragenyx Pharmaceutical$673.0m20.2%
179thDoximity$644.9m13.1%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Kiniksa Pharmaceuticals International

How much revenue did Kiniksa Pharmaceuticals International make in fiscal 2025?
Kiniksa Pharmaceuticals International reported revenue of $677.6m for fiscal 2025, compared with $423.2m in fiscal 2024.
How much has the revenue of Kiniksa Pharmaceuticals International grown?
Between fiscal 2021 and fiscal 2025 it went from $38.5m to $677.6m: 1,657.9% more, an average growth of 104.8% a year.
What was the best year for revenue at Kiniksa Pharmaceuticals International?
Of its last 5 fiscal years, fiscal 2025, with $677.6m.
Where does Kiniksa Pharmaceuticals International rank in its sector by revenue?
It ranks 177th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Kiniksa Pharmaceuticals International come from?
From the annual report (Form 10-K) that Kiniksa Pharmaceuticals International files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Kiniksa Pharmaceuticals International files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Kiniksa Pharmaceuticals International: the Kiniksa Pharmaceuticals International page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.